Please login to the form below

cladribine

This page shows the latest cladribine news and features for those working in and with pharma, biotech and healthcare.

despite greater competition from drugs like Roche’s Ocrevus (ocrelizumab), Novartis’ Mayzent (siponimod) and Merck KGaA’s Mavenclad (cladribine).

MS and cholesterol drugs picked for new UK rapid uptake push

Merck’s Mavenclad (cladribine) for treating highly active relapsing-remitting multiple sclerosis in adults - A drug for multiple sclerosis with a novel mode of action, high efficacy and a low treatment
Sanofi licences Principia MS drug in $805m deal

The three established players in the oral MS therapy category are also about to see additional competition from new entrant Merck KGaA, which bagged EU approval for Mavenclad (cladribine) in August.
Merck mulls sale of consumer health division

The news comes a few days after Merck picked up an important new approval for its pharma division in Europe, with the EMA clearing Mavenclad (cladribine) for the treatment of
Merck gets CHMP backing for long-delayed oral MS drug

Cladribine, which will be branded as Mavenclad, was originally rejected by the committee in 2010. ... The company thinks oral cladribine has a key differentiator from its rivals, which require daily dosing.
Avelumab costs peg back profit at Merck KGaA

Avelumab and other pipeline candidates such as oral MS therapy cladribine have assumed even more importance for Merck since it abandoned plans to seek approval of evofosfamide in advanced soft tissue

More from news
Approximately 2 fully matching, plus 26 partially matching documents found.

XenoPort appoints chief medical officer

Prior to joining Biogen Idec Dr Kim was with Merck Serono, serving as medical director for the phase III programme of cladribine, which failed to impress in MS.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Add my company

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?: Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives: Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies: Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...